Safety, tolerability, pharmacokinetics, pharmacodynamics empagliflozin

Oral administration of empagliflozin at doses of 10 mg, 25 mg or 100 mg once daily over 28 days resulted in significant increases in UGE and reductions in blood glucose compared with placebo, and were well tolerated in patients with type 2 diabetes (Diabetes, Obesity and Metabolism)